Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - NGM BIOPHARMACEUTICALS INC | ngm-ex321_8.htm |
| EX-31.2 - EX-31.2 - NGM BIOPHARMACEUTICALS INC | ngm-ex312_1163.htm |
| EX-31.1 - EX-31.1 - NGM BIOPHARMACEUTICALS INC | ngm-ex311_7.htm |
| EX-21.1 - EX-21.1 - NGM BIOPHARMACEUTICALS INC | ngm-ex211_10.htm |
| EX-10.18 - EX-10.18 - NGM BIOPHARMACEUTICALS INC | ngm-ex1018_397.htm |
| EX-10.17 - EX-10.17 - NGM BIOPHARMACEUTICALS INC | ngm-ex1017_396.htm |
| 10-K - 10-K - NGM BIOPHARMACEUTICALS INC | ngm-10k_20201231.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
|
1. |
Registration Statement (Form S-8 No. 333-230725) pertaining to NGM Biopharmaceuticals, Inc. Amended and Restated 2018 Equity Incentive Plan and NGM Biopharmaceuticals, Inc. 2019 Employee Stock Purchase Plan; |
|
|
2. |
Registration Statement (Form S-8 No. 333-237243) pertaining to NGM Biopharmaceuticals, Inc. Amended and Restated 2018 Equity Incentive Plan; and |
|
|
3. |
Registration Statement (Form S-3 No. 333-238991) and related prospectus and prospectus supplements of NGM Biopharmaceuticals, Inc.; |
of our report dated March 15, 2021, with respect to the consolidated financial statements of NGM Biopharmaceuticals, Inc., included in this Annual Report (Form 10-K) of NGM Biopharmaceuticals, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Redwood City, California
March 15, 2021